| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $0 | 0 | 0 |
Sells | $788,872 | 9 | 100 |
| Lorton Kenneth Patrick | EVP, CTO & COO, Software | 0 | $0 | 1 | $24,064 | $-24,064 |
| Dugan Margaret | Chief Medical Officer | 0 | $0 | 1 | $29,387 | $-29,387 |
| Abel Robert Lorne | See Remarks | 0 | $0 | 1 | $31,838 | $-31,838 |
| Herman Jenny | SVP & Controller | 0 | $0 | 2 | $35,045 | $-35,045 |
| Porges Geoffrey Craig | EVP & CFO | 0 | $0 | 1 | $119,484 | $-119,484 |
| Tran Yvonne | EVP, CLO & CPO | 0 | $0 | 2 | $129,484 | $-129,484 |
| Akinsanya Karen | President of R&D, Therapeutics | 0 | $0 | 1 | $419,570 | $-419,570 |
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Over the last 12 months, insiders at Schrödinger, Inc. have bought $0 and sold $788,872 worth of Schrödinger, Inc. stock.
On average, over the past 5 years, insiders at Schrödinger, Inc. have bought $111,386 and sold $67.73M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,115 shares for transaction amount of $111,386 was made by Lebowitz Joel (EVP & CFO) on 2021‑02‑05.
| 2025-10-16 | Sale | Dugan Margaret | Chief Medical Officer | 1,395 0.002% | $21.07 | $29,387 | -11.64% | |
| 2025-04-14 | Sale | Akinsanya Karen | President of R&D, Therapeutics | 16,723 0.0315% | $25.09 | $419,570 | -22.65% | |
| 2025-03-06 | Sale | Herman Jenny | SVP & Controller | 666 0.0009% | $21.11 | $14,059 | -2.33% | |
| 2025-03-03 | Sale | Porges Geoffrey Craig | EVP & CFO | 5,491 0.0077% | $21.76 | $119,484 | -3.04% | |
| 2025-02-18 | Sale | Tran Yvonne | EVP, CLO & CPO | 3,902 0.006% | $28.00 | $109,256 | -20.76% | |
| 2025-02-11 | Sale | Lorton Kenneth Patrick | EVP, CTO & COO, Software | 985 0.0013% | $24.43 | $24,064 | -15.68% | |
| 2025-02-11 | Sale | Herman Jenny | SVP & Controller | 859 0.0011% | $24.43 | $20,985 | -15.68% | |
| 2025-02-11 | Sale | Tran Yvonne | EVP, CLO & CPO | 828 0.0011% | $24.43 | $20,228 | -15.68% | |
| 2025-02-10 | Sale | Abel Robert Lorne | See Remarks | 1,225 0.0017% | $25.99 | $31,838 | -17.87% | |
| 2024-10-15 | Sale | Dugan Margaret | Chief Medical Officer | 1,531 0.002% | $17.78 | $27,226 | +19.07% | |
| 2024-03-04 | Sale | Porges Geoffrey Craig | EVP & CFO | 3,315 0.0048% | $26.35 | $87,360 | -15.45% | |
| 2024-02-12 | Sale | Lorton Kenneth Patrick | EVP, CTO & COO, Software | 901 0.0013% | $28.29 | $25,489 | -24.90% | |
| 2024-02-12 | Sale | Tran Yvonne | EVP, CLO & CPO | 758 0.0011% | $28.29 | $21,444 | -24.90% | |
| 2024-02-12 | Sale | Herman Jenny | SVP & Controller | 787 0.0011% | $28.29 | $22,264 | -24.90% | |
| 2024-02-12 | Sale | Abel Robert Lorne | See Remarks | 1,205 0.0016% | $27.55 | $33,198 | -24.90% | |
| 2023-08-09 | Sale | Lorton Kenneth Patrick | EVP & Chief Technology Officer | 10,000 0.0141% | $40.06 | $400,642 | -33.24% | |
| 2023-06-30 | Sale | Tran Yvonne | EVP, CLO & CPO | 12,040 0.0169% | $50.00 | $602,000 | -45.00% | |
| 2023-05-23 | Sale | Lorton Kenneth Patrick | EVP & Chief Technology Officer | 10,000 0.0146% | $40.06 | $400,587 | -21.37% | |
| 2023-05-23 | Sale | Tran Yvonne | EVP, CLO & CPO | 7,960 0.0116% | $40.01 | $318,461 | -21.37% | |
| 2023-05-22 | Sale | Tran Yvonne | EVP, CLO & CPO | 15,000 0.0189% | $35.04 | $525,632 | -22.04% |
| Lorton Kenneth Patrick | EVP, CTO & COO, Software | 41076 0.0558% | $741,832.56 | 0 | 5 | |
| Porges Geoffrey Craig | EVP & CFO | 27544 0.0374% | $497,444.64 | 0 | 2 | |
| Herman Jenny | SVP & Controller | 27349 0.0371% | $493,922.94 | 0 | 7 | |
| Dugan Margaret | Chief Medical Officer | 24574 0.0334% | $443,806.44 | 0 | 2 | |
| Akinsanya Karen | President of R&D, Therapeutics | 15625 0.0212% | $282,187.50 | 0 | 9 | |
| Tran Yvonne | EVP, CLO & CPO | 11135 0.0151% | $201,098.10 | 0 | 11 | |
| Abel Robert Lorne | See Remarks | 8115 0.011% | $146,556.90 | 0 | 9 | |
| BILL & MELINDA GATES FOUNDATION TRUST | 10 percent owner | 6981664 9.4776% | $126.09M | 1 | 3 | +110.06% |
| SHAW DAVID E | 10 percent owner | 6103042 8.2849% | $110.22M | 0 | 109 | |
| Friesner Richard | director | 504450 0.6848% | $9.11M | 0 | 5 | |
| Flynn James E | 10 percent owner | 250000 0.3394% | $4.51M | 1 | 0 | +110.06% |
| Farid Ramy | President & CEO | 184432 0.2504% | $3.33M | 0 | 4 | |
| Weiser Jorg | EVP & Managing Director | 117052 0.1589% | $2.11M | 0 | 4 | |
| Brauner Shane | See Remarks | 24867 0.0338% | $449,098.02 | 0 | 4 | |
| Daniel Jennifer | EVP & Chief HR Officer | 6688 0.0091% | $120,785.28 | 0 | 20 | |
| Lynton Michael | director | 0 0% | $0 | 0 | 3 | |
| Sender Gary | director | 0 0% | $0 | 0 | 1 | |
| D'Cruz Cony | EVP & Chief Business Officer | 0 0% | $0 | 0 | 13 | |
| Thornberry Nancy | director | 0 0% | $0 | 0 | 2 | |
| Lebowitz Joel | EVP & CFO | 0 0% | $0 | 1 | 13 | <0.0001% |
| Kapeller-Libermann Rosana | director | 0 0% | $0 | 0 | 1 | |
| Ardai Charles | 10 percent owner | 0 0% | $0 | 0 | 2 |
| Increased Positions | 91 | +29.84% | 7M | +10.07% |
| Decreased Positions | 134 | -43.93% | 8M | -11.75% |
| New Positions | 27 | New | 806,427 | New |
| Sold Out Positions | 37 | Sold Out | 4M | Sold Out |
| Total Postitions | 262 | -14.1% | 70M | -1.68% |
| Blackrock, Inc. | $168,658.00 | 14.71% | 9.56M | -215,974 | -2.21% | 2025-09-30 |
| Gates Foundation Trust | $123,157.00 | 10.74% | 6.98M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $111,821.00 | 9.75% | 6.34M | -277,572 | -4.2% | 2025-09-30 |
| Rubric Capital Management Lp | $92,942.00 | 8.11% | 5.27M | +268,817 | +5.38% | 2025-09-30 |
| Sumitomo Mitsui Trust Group, Inc. | $80,343.00 | 7.01% | 4.55M | +904,619 | +24.78% | 2025-09-30 |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Ame | $58,277.00 | 5.08% | 3.3M | -111,621 | -3.27% | 2025-09-30 |
| Amova Asset Management Americas, Inc. | $46,551.00 | 4.06% | 2.64M | +47,443 | +1.83% | 2025-09-30 |
| Lazard Asset Management Llc | $41,391.00 | 3.61% | 2.35M | +927,234 | +65.33% | 2025-09-30 |
| State Street Corp | $38,897.00 | 3.39% | 2.21M | +19,278 | +0.88% | 2025-09-30 |
| Stephens Investment Management Group Llc | $38,685.00 | 3.37% | 2.19M | -68,300 | -3.02% | 2025-09-30 |